Kevin Bielamowicz

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Role not yet determined

UAMS

20 h-index 166 pubs 3,320 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Kevin Bielamowicz's research focuses on the development and application of CAR T-cell therapies for solid tumors, particularly glioblastoma and other central nervous system malignancies. His work investigates strategies to overcome challenges in CAR T-cell therapy, such as tumor antigen escape and interpatient variability. Bielamowicz has published on the use of HER2-specific CAR T-cells and tandem CAR T-cells targeting multiple antigens for improved efficacy.

His research group also explores locoregional delivery methods for CAR T-cells, including delivery to the cerebrospinal fluid for treating metastatic medulloblastoma and ependymoma. Bielamowicz has been involved in clinical trials, including the ReNeu trial for plexiform neurofibromas in adults and children with neurofibromatosis type 1. His scholarly output includes work on TEM8/ANTXR1-specific CAR T-cells for triple-negative breast cancer and studies on the clinical landscape of constitutional mismatch-repair deficiency syndrome.

Bielamowicz's scholarly metrics include an h-index of 20, with 166 total publications and over 3,300 citations. He is recognized as a highly cited researcher. Key collaborators at the University of Arkansas for Medical Sciences include Murat Gökden, Sateesh Jayappa, Kathleen Danielle Aldrich, and Gregory W. Albert.

Metrics

h-index: 20
Publications: 166
Citations: 3,320

Selected Publications

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance (2025)

International Journal of Molecular Sciences 1 citation DOI OpenAlex
TARGETED INHIBITION IN PEDIATRIC MET and ALK ALTERED PEDIATRIC HIGH GRADE GLIOMAS: OBJECTIVE RESPONSES FOLLOWED BY TREATMENT RESISTANCE (2025)

DOI OpenAlex
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma (2025)

Cancers 3 citations DOI OpenAlex
A rare presentation of pediatric germinoma mimicking optic pathway glioma: illustrative case (2025)

Journal of Neurosurgery Case Lessons DOI OpenAlex
ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003) (2025)

Neurology DOI OpenAlex
QOL-08. HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL (2024)

Neuro-Oncology DOI OpenAlex
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma (2024)

Journal of Clinical Oncology 97 citations DOI OpenAlex